Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.
Type:
Grant
Filed:
October 6, 2006
Date of Patent:
November 25, 2008
Assignees:
Yale University, Biogen Idec MA Inc.
Inventors:
Stephen Strittmatter, Richard L. Cate, Dinah W. Y. Sah
Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.
Type:
Application
Filed:
July 10, 2006
Publication date:
November 20, 2008
Applicant:
Biogen Idec MA.
Inventors:
Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W.T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
Abstract: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.
Type:
Grant
Filed:
April 21, 2004
Date of Patent:
November 18, 2008
Assignees:
Biogen Idec MA Inc., Emory University
Inventors:
Jeffrey L. Browning, Maryann Puglielli, Rafi Ahmed
Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
Type:
Grant
Filed:
July 10, 2000
Date of Patent:
November 18, 2008
Assignee:
Biogen Idec Inc.
Inventors:
Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.
Type:
Grant
Filed:
March 16, 2004
Date of Patent:
November 4, 2008
Assignee:
Biogen Idec MA Inc.
Inventors:
Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
Abstract: A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.
Type:
Grant
Filed:
January 31, 2003
Date of Patent:
October 28, 2008
Assignee:
Biogen Idec MA Inc.
Inventors:
Dinah Wen-Yee Sah, R. Blake Pepinsky, Paula Ann Boriack-Sjodin, Stephan S. Miller, Anthony Rossomando, Laura Silvian
Abstract: A system and method for monitoring process equipment includes collecting information from the process equipment. The collected information is statistically analyzed. One or more signatures indicating the overall status or health of one or more pieces of equipment can be developed.
Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
Type:
Application
Filed:
August 18, 2005
Publication date:
October 9, 2008
Applicant:
Biogen Idec MA Inc.
Inventors:
Anthony Rossomando, R. Blake Pepinsky, Bangjian Gong
Abstract: Fumaric acid amides of the general formula (I) wherein R1 represents OR3 or a D- or L-amino acid radical —NH—CHR4—COOH bonded via an amide bond, wherein R3 is hydrogen, a straight-chained or branched, optionally substituted C1-24 alkyl radical, a phenyl radical or C6-10 aralkyl radical and R4 is a side chain of a natural or synthetic amino acid and R2 represents a D- or L-amino acid radical —NH—CHR5—COOH bonded via an amide bond or a peptide radical comprising 2 to 100 amino acids bonded via an amide bond, wherein R5 is a side chain of a natural or synthetic amino acid, are used for preparing a drug (1) for the therapy of an autoimmune disease; (2) for use in transplantation medicine; (3) for the therapy of mitochondrial diseases; or (4) for the therapy of NF-kappaB mediated diseases.
Abstract: This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-?-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.
Type:
Grant
Filed:
December 23, 2004
Date of Patent:
September 30, 2008
Assignee:
Biogen Idec MA Inc.
Inventors:
Ellen Garber, Kenneth Simon, Jose William Saldanha
Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
Type:
Application
Filed:
February 12, 2008
Publication date:
September 25, 2008
Applicants:
BIOGEN IDEC MA INC., NSGENE A/S
Inventors:
Dinah W.Y. Sah, Teit E. Johansen, Anthony Rossomando
Abstract: The present invention relates in part to compounds of formulas (I) and (III): and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.
Type:
Application
Filed:
April 28, 2005
Publication date:
September 25, 2008
Applicants:
ICOS Corporation, Biogen Idec MA Inc.
Inventors:
Kevin Guckian, Daniel Scott, Irina Jacobson, C.Gregory Sowell
Abstract: This invention relates to compositions and methods comprising “lymphotoxin-? receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
Type:
Grant
Filed:
February 15, 2002
Date of Patent:
September 23, 2008
Assignee:
Biogen Idec MA Inc.
Inventors:
Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.
Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.